Health Equity in Clinical Trials Best Practices Database

Key elements of the study diversity plan. 

The Robert A. Winn Diversity in Clinical Trials Award program, created by the Bristol Myers Squibb Foundation, develops clinical investigators who are racially and ethnically diverse or who are committed to increasing diversity in clinical trials, and exposes promising, underrepresented minority medical students to clinical research career pathways.

Bristol Myers Squibb (BMS) is working hard to change that, and we’re gaining recognition as an industry leader in making clinical trials readily accessible to a broad range of patients around the world. 

The Reagan-Udall Foundation for the FDA is pleased to announce the launch of its Regulatory Science, Innovation, and Health Equity Fellowship Program. Increasing diversity in regulatory science serves to bring varied perspectives into the field and generate more meaningful results. 

The Max Foundation and BeiGene announced a collaboration to provide access to BRUKINSA (zanubrutinib) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) in 29 low- and middle-income countries over the next three years.

FDA Diversity Plan Early Insights and Considerations

Equitable Breakthroughs in Medicine Development, a first-of-its-kind, cross-collaborative, community-based effort, seeks to tackle systemic challenges to clinical trial participation and share our findings broadly to help drive change.

Gilead will contribute $14 million over four years to the Bristol Myers Squibb Foundation’s career development program, which centers on elevating physicians of color.

Gilead Sciences, Inc. announced it is providing a total of $12.6 million in grant funding to 19 organizations working to improve the HIV landscape for Black women and girls in the United States. 

The Robert A. Winn Diversity in Clinical Trials Award Program aims to train, develop and mentor more than 308 clinical trialists and 308 medical students by 2027 who are diverse or who have a demonstrated commitment to clinical trial diversity.

How Moderna is applying what was learned from its COVID-19 trial experience and how it is being applied to Moderna’s CMV Phase 3 study.

How creating a diversity plan early in development can make drug development more efficient.

The Accessibility by Design (AbD) in Clinical Research Toolkit is a comprehensive resource intended to be used by sponsors, institutions, investigators, ethics committees/IRBs, participants and Patient advocacy groups to support greater inclusion of people with disabilities in clinical research.

The Ferring Grants Program for Equity in Reproductive Medicine and Maternal Health aims to fund projects in basic and translational research, clinical research, epidemiology and prevention research and social science research.

Clinical trials are essential for the development of safe and effective health care products. Learn more about the latest trends in the sector – from greater accessibility to increased diversity – and why they are essential for growth.

Teva investigates why it is vital for drug development and outlines its work in this space.

BlackDoctor.org (BDO) and Merck are working together to improve Black American participation in clinical trials. Merck was the first to sign on to list its trials on BDO’s Clinical Trials Resource Center (CTRC).

The aim of this study was to establish a transparent and reproducible process for setting trial diversity enrollment goals informed by the disease epidemiology.

The initiative, “Change the Odds: Uniting to Improve Cancer Outcomes” aims to enhance awareness of and access to cancer screening, clinical trials and support in medically underrepresented communities across the United States.

Every two seconds, someone in the world is diagnosed with cancer.¹ It’s a disease that knows no borders, doesn’t distinguish between race or religion, and pays no mind to whether a person is rich or poor. The great equalizer, it touches every corner of the globe.

World Cancer Day 2024 the theme is still "Close the Care Gap". The campaign is all about understanding and recognising the inequities in cancer care around the globe. This World Cancer Day, we recognise the power of working together.

The American Cancer Society (ACS) and Pfizer launched on February 5th, “Change the Odds: Uniting to Improve Cancer OutcomesTM,” a three-year initiative to address disparities in cancer care. Through $15 million in funding from Pfizer, the initiative aims to improve health outcomes in medically underrepresented communities across the United States by enhancing awareness of and access to cancer screenings, clinical trial opportunities, patient support and comprehensive navigation.

How Accelerated Cure Project (ACP) and the Multiple Sclerosis Association of America (MSAA) collaborated to further diverse clinical trial participation.

How Merck increased clinical trial diversity using Customized Tools, Applications and a Dynamic Enrollment Tracker.

To provide learnings and best practice suggestions for others seeking to pursue similar efforts, this report provides a detailed overview of how Pfizer and a network of cancer patient advocacy leaders collectively designed processes and built this foundational infrastructure – an ecosystem – for partnering to advance patient centricity.

My Living Legacy, created in partnership with the Tigerlily Foundation to empower Black and other BIPOC people to more deeply understand and trust in clinical trials and to consider clinical trials as a possible treatment option for life-threatening diseases like breast cancer.

Find out how GSK is working with organizations like MiOra to ensure that women from underserved communities are represented in clinical trials for Ovarian Cancer.

Multiple Myeloma disproportionately impacts African Americans. To get ahead of this disease, we're working with patient advocates to increase the number of African American participants in clinical trials.

We investigate the racial and ethnic demographic diversity of US-based participants in GSK-sponsored interventional trials. We also assess the evaluation of demographic diversity against US Census and epidemiologic data.

Insmed Inc. is teaming up with award-winning actress Jane Seymour for a campaign to raise awareness of gender and age biases in health care.

The IQVIA Institute has assembled a multi-stakeholder panel to explore the challenges, key levers and scenarios for consideration in oncology clinical trial diversity planning processes and in designing and delivering those trials.

IQVIA experts evaluate how best to set diversity goals and ensure clinical trials are more accessible by taking a proactive approach to diversity and inclusion that begins at the earliest stages of epidemiological review and protocol design.

We believe that by leveraging the varied backgrounds of our more than 35,000 employees – and by driving actionable and measurable strategies to improve DEI, including diversity within our clinical trials – we can better deliver scientific breakthroughs.

At the height of the COVID-19 pandemic, we launched mobile research RVs to test a potential COVID therapy in nursing homes across the U.S. Now we’re expanding our fleet of mobile units to improve access to other clinical studies—and transform how we research potential new medicines.

Eli Lilly and Company announced results from a first-of-its-kind study of lebrikizumab specifically designed for people with skin of color and moderate-to-severe atopic dermatitis, commonly called eczema. In this study, treatment with lebrikizumab, an investigational medicine, showed improvement in skin clearance and itch relief.